NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis $7.05 +0.19 (+2.77%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.05▼$7.0950-Day Range$6.86▼$9.4152-Week Range$5.57▼$13.14Volume1,174 shsAverage Volume9,288 shsMarket Capitalization$20.87 millionP/E RatioN/ADividend YieldN/APrice Target$28.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Oncternal Therapeutics alerts: Email Address Oncternal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside301.9% Upside$28.33 Price TargetShort InterestHealthy0.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.63) to ($10.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.86 out of 5 starsMedical Sector436th out of 936 stocksPharmaceutical Preparations Industry200th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingOncternal Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncternal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Oncternal Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.80% of the float of Oncternal Therapeutics has been sold short.Short Interest Ratio / Days to CoverOncternal Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncternal Therapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncternal Therapeutics does not currently pay a dividend.Dividend GrowthOncternal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCT. Previous Next 3.9 News and Social Media Coverage News SentimentOncternal Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oncternal Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for ONCT on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Oncternal Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncternal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.20% of the stock of Oncternal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.05% of the stock of Oncternal Therapeutics is held by institutions.Read more about Oncternal Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncternal Therapeutics are expected to grow in the coming year, from ($11.63) to ($10.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncternal Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncternal Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncternal Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oncternal Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Oncternal Therapeutics Stock (NASDAQ:ONCT)Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Read More ONCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCT Stock News HeadlinesJuly 23 at 5:14 AM | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.comJuly 16, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Oncternal Therapeutics (NASDAQ:ONCT)July 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 11, 2024 | globenewswire.comOncternal Therapeutics to Present in JonesTrading Healthcare SummitMay 30, 2024 | globenewswire.comOncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerMay 11, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Oncternal Therapeutics Inc Earnings CallMay 9, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024July 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.May 9, 2024 | sfgate.comOncternal Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)May 2, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)April 19, 2024 | uk.finance.yahoo.comEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline DrugsApril 18, 2024 | globenewswire.comOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerSee More Headlines Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCT CUSIPN/A CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees27Year FoundedN/APrice Target and Rating Average Stock Price Target$28.33 High Stock Price Target$40.00 Low Stock Price Target$19.00 Potential Upside/Downside+299.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($12.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,480,000.00 Net Margins-3,160.73% Pretax Margin-3,160.73% Return on Equity-107.67% Return on Assets-91.04% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$790,000.00 Price / Sales26.57 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.70Miscellaneous Outstanding Shares2,960,000Free Float2,628,000Market Cap$20.99 million OptionableNo Data Beta1.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Comp: $881.36kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Comp: $602.84kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Comp: $648.53kDr. Rajesh Krishnan Ph.D. (Age 51)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentMs. Anita WisethSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsPMV PharmaceuticalsNASDAQ:PMVPBeyondSpringNASDAQ:BYSIKronos BioNASDAQ:KRONMarinus PharmaceuticalsNASDAQ:MRNSChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsPasadena Private Wealth LLCBought 25,000 shares on 7/19/2024Ownership: 0.845%Richmond Brothers Inc.Sold 469,346 shares on 5/10/2024Ownership: 0.834%Quantum Private Wealth LLCBought 27,806 shares on 5/7/2024Ownership: 0.939%Robert James WillsBought 3,086 shares on 4/8/2024Total: $27,650.56 ($8.96/share)Robert James WillsBought 6,914 shares on 3/28/2024Total: $58,630.72 ($8.48/share)View All Insider TransactionsView All Institutional Transactions ONCT Stock Analysis - Frequently Asked Questions How have ONCT shares performed this year? Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 34.3% and is now trading at $7.05. View the best growth stocks for 2024 here. How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.18 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative trailing twelve-month return on equity of 107.67%. When did Oncternal Therapeutics' stock split? Oncternal Therapeutics's stock reverse split before market open on Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Oncternal Therapeutics' major shareholders? Oncternal Therapeutics' top institutional investors include Pasadena Private Wealth LLC (0.84%). Insiders that own company stock include Robert James Wills, Salim Yazji, Richard G Vincent, James B Breitmeyer, Chase C Leavitt, Gunnar F Kaufmann and David F Hale. View institutional ownership trends. How do I buy shares of Oncternal Therapeutics? Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:ONCT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.